Estrella Immunopharma (ESLA) Competitors $1.00 +0.01 (+1.02%) As of 03/25/2025 03:56 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock ESLA vs. ZNTL, ACTU, OGI, SAVA, DERM, EPRX, ALEC, LXEO, TELO, and GNLXShould you be buying Estrella Immunopharma stock or one of its competitors? The main competitors of Estrella Immunopharma include Zentalis Pharmaceuticals (ZNTL), Actuate Therapeutics (ACTU), Organigram (OGI), Cassava Sciences (SAVA), Journey Medical (DERM), Eupraxia Pharmaceuticals (EPRX), Alector (ALEC), Lexeo Therapeutics (LXEO), Telomir Pharmaceuticals (TELO), and Genelux (GNLX). These companies are all part of the "pharmaceutical products" industry. Estrella Immunopharma vs. Zentalis Pharmaceuticals Actuate Therapeutics Organigram Cassava Sciences Journey Medical Eupraxia Pharmaceuticals Alector Lexeo Therapeutics Telomir Pharmaceuticals Genelux Estrella Immunopharma (NASDAQ:ESLA) and Zentalis Pharmaceuticals (NASDAQ:ZNTL) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, profitability, community ranking, valuation, institutional ownership, risk, earnings, media sentiment and analyst recommendations. Does the MarketBeat Community believe in ESLA or ZNTL? Zentalis Pharmaceuticals received 60 more outperform votes than Estrella Immunopharma when rated by MarketBeat users. However, 100.00% of users gave Estrella Immunopharma an outperform vote while only 62.24% of users gave Zentalis Pharmaceuticals an outperform vote. CompanyUnderperformOutperformEstrella ImmunopharmaOutperform Votes1100.00% Underperform VotesNo VotesZentalis PharmaceuticalsOutperform Votes6162.24% Underperform Votes3737.76% Do institutionals & insiders have more ownership in ESLA or ZNTL? 0.3% of Estrella Immunopharma shares are held by institutional investors. 55.1% of Estrella Immunopharma shares are held by insiders. Comparatively, 3.6% of Zentalis Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. Is ESLA or ZNTL more profitable? Zentalis Pharmaceuticals' return on equity of -43.91% beat Estrella Immunopharma's return on equity.Company Net Margins Return on Equity Return on Assets Estrella ImmunopharmaN/A -195.77% -157.28% Zentalis Pharmaceuticals N/A -43.91%-34.96% Do analysts rate ESLA or ZNTL? Estrella Immunopharma presently has a consensus target price of $16.00, suggesting a potential upside of 1,500.16%. Zentalis Pharmaceuticals has a consensus target price of $8.24, suggesting a potential upside of 340.88%. Given Estrella Immunopharma's stronger consensus rating and higher possible upside, research analysts clearly believe Estrella Immunopharma is more favorable than Zentalis Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Estrella Immunopharma 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Zentalis Pharmaceuticals 0 Sell rating(s) 5 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.44 Does the media refer more to ESLA or ZNTL? In the previous week, Zentalis Pharmaceuticals had 1 more articles in the media than Estrella Immunopharma. MarketBeat recorded 2 mentions for Zentalis Pharmaceuticals and 1 mentions for Estrella Immunopharma. Estrella Immunopharma's average media sentiment score of 1.89 beat Zentalis Pharmaceuticals' score of 0.93 indicating that Estrella Immunopharma is being referred to more favorably in the media. Company Overall Sentiment Estrella Immunopharma Very Positive Zentalis Pharmaceuticals Positive Which has more volatility and risk, ESLA or ZNTL? Estrella Immunopharma has a beta of 0.4, indicating that its stock price is 60% less volatile than the S&P 500. Comparatively, Zentalis Pharmaceuticals has a beta of 1.75, indicating that its stock price is 75% more volatile than the S&P 500. Which has better earnings & valuation, ESLA or ZNTL? Estrella Immunopharma has higher earnings, but lower revenue than Zentalis Pharmaceuticals. Estrella Immunopharma is trading at a lower price-to-earnings ratio than Zentalis Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioEstrella ImmunopharmaN/AN/A-$7.31M-$0.26-3.85Zentalis Pharmaceuticals$40.56M3.29-$292.19M-$2.49-0.75 SummaryEstrella Immunopharma and Zentalis Pharmaceuticals tied by winning 8 of the 16 factors compared between the two stocks. Remove Ads Get Estrella Immunopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for ESLA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ESLA vs. The Competition Export to ExcelMetricEstrella ImmunopharmaBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$36.18M$3.03B$5.68B$8.30BDividend YieldN/A1.54%4.55%4.02%P/E Ratio-3.8529.9524.5819.25Price / SalesN/A447.85388.0794.32Price / CashN/A168.6838.1634.64Price / Book8.334.227.084.46Net Income-$7.31M-$71.72M$3.19B$247.07M7 Day Performance1.00%-3.44%-0.94%0.14%1 Month Performance-9.10%-9.94%3.55%-4.39%1 Year Performance-20.62%-23.03%14.29%4.85% Estrella Immunopharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ESLAEstrella Immunopharma2.4847 of 5 stars$1.00+1.0%$16.00+1,500.2%-11.5%$36.18MN/A-3.85N/APositive NewsGap DownZNTLZentalis Pharmaceuticals2.2763 of 5 stars$1.98+3.7%$8.24+316.4%-86.2%$141.11M$40.56M-0.80160Gap UpACTUActuate TherapeuticsN/A$7.20+6.7%$20.00+177.8%N/A$140.63MN/A0.0010OGIOrganigram0.6999 of 5 stars$1.11flatN/A-57.5%$140.10M$166.12M-2.92860News CoveragePositive NewsSAVACassava Sciences3.9042 of 5 stars$2.80-1.4%$111.50+3,882.1%-90.4%$137.20MN/A-2.0330Analyst ForecastNews CoverageGap DownDERMJourney Medical2.5702 of 5 stars$6.54+13.9%$9.67+47.8%+121.9%$136.62M$57.77M-6.9690High Trading VolumeEPRXEupraxia Pharmaceuticals2.3473 of 5 stars$3.65-4.6%$10.50+188.1%N/A$136.26MN/A-5.0629Earnings ReportPositive NewsALECAlector3.7363 of 5 stars$1.37+1.5%$3.50+155.5%-78.4%$135.75M$100.56M-0.81270LXEOLexeo Therapeutics2.4934 of 5 stars$4.09+50.9%$23.60+477.0%-69.6%$135.24M$650,000.00-1.2958Earnings ReportAnalyst ForecastAnalyst RevisionNews CoverageGap UpHigh Trading VolumeTELOTelomir Pharmaceuticals1.8723 of 5 stars$4.53-0.7%$15.00+231.1%-21.8%$134.83MN/A-7.811Gap DownGNLXGenelux1.1864 of 5 stars$3.89-1.0%$18.25+369.2%-44.6%$134.35M$8,000.00-4.0910Analyst ForecastAnalyst RevisionNews CoverageGap Down Remove Ads Related Companies and Tools Related Companies Zentalis Pharmaceuticals Competitors Actuate Therapeutics Competitors Organigram Competitors Cassava Sciences Competitors Journey Medical Competitors Eupraxia Pharmaceuticals Competitors Alector Competitors Lexeo Therapeutics Competitors Telomir Pharmaceuticals Competitors Genelux Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ESLA) was last updated on 3/26/2025 by MarketBeat.com Staff From Our PartnersTrump’s Final Plan Presidential insider exposes shocking plot to reshape U.S. economy: The 2025 Trump Reset -- Inside Trump’...Porter & Company | SponsoredNew “Trump” currency proposed in DCAccording to one of the most connected men in Washington… A surprising new bill was just introduced in Wash...Paradigm Press | SponsoredDOGE could send 6 AI stocks through the roofStay alert for Elon Musk and the Department of Government Efficiency's next move … Expect an announcement f...Weiss Ratings | SponsoredTrump’s Secret WeaponHave you looked at the stock market recently? Millions of investors are scrambling trying to figure out what's...American Alternative | SponsoredNvidia’s CEO: “This Will Be a Multitrillion-Dollar Industry."If you missed out on the big boom in Nvidia… Listen up, because according to Nvidia's own CEO… Elon Musk...Brownstone Research | SponsoredHere’s Why Tesla Insiders are Dumping SharesTesla has been on a losing streak ever since Elon Musk first visited the White House in early 2025. Our res...Behind the Markets | SponsoredTrump’s Bitcoin Reserve is No Accident…Bryce Paul believes this is the #1 coin to buy right now The catalyst behind this surge is a massive new b...Crypto 101 Media | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Estrella Immunopharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Estrella Immunopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy ESLA Stock Free ESLA Stock Alerts